FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
Find answers to all your questions on live PFIZER message board: Is PFIZER buy or sell? Should I buy PFIZER shares? Why are PFIZER shares falling? Should I invest in PFIZER stock?

forum

PFIZER Share Price Discussion

Pfizer Ltd.
NSE: PFIZER | BSE: 500680 | ISIN: INE182A01018 | Sector: Pharmaceuticals and health care

**Pfizer - Q4 FY20 (Audited –Cons)**
CMP: 4,078
Total revenue from operations 502 Cr
536 Cr (-6.35%) YoY | 538 Cr (-6.65%) QoQ
Year ending revenue: 2,152 Cr Vs. 2,082 Cr (3.34%)
Net Profit of 103 Cr
109 Cr (-1.92%) YoY 139 Cr (-21.59%) QoQ
Year ending Net profit: 509 Cr Vs. 429 Cr (-18.61%)
EPS (in Rs.) 22.52
23.93 YoY | 30.40 QoQ
Year ending EPS: 111.28 Vs. 93.78
View: Result is below expectation. YoY and QoQ revenue and profit both have declined. EBITDA also declined in both the quarter.
**Business Updates & Highlights**:
Q4FY20 EBITDA is around INR 108 Cr Vs. 150.7 Cr in Q4FY19 Vs. 133.2 Cr in Q3FY20 therefore declined by 60.1% in YoY and declined by 18.8% in QoQ. EBITDA margin in Q4FY20 is 21.5% Vs. 27.9% in Q4FY19 Vs. 24.7% in QoQ.
FY20 EBITDA is INR 571.8 Cr Vs. 565.8 Cr in FY19 therefore up by 1.1% in YoY. EBITDA margin is 26.5% Vs. 27.1% in YoY.
The Board of Directors at its Meeting held on 27 April 2020 declared a special (interim) dividend of ₹320 per equity share of ₹10 each (3200%) for the financial year ended 31 March 2020.
**In addition to the above, the Board of Directors had further at its Meeting held today, recommended a final dividend of ₹10 per equity share of ₹10 each (100%) for the financial year ended 31 March 2020**
**Financial**
ROE and ROCE is around INR 24% and 15% respectively and book value per share is around INR 690 and share is currently trading at 6x of its book value. Company is currently trading at annualized PE of around 37 which is fair as per industry benchmark. Promoter holding is around 63.9% in the company which is very fair and stable. FIIs and mutual fund hold around 3.7% and 9.3% in the company. Cash and cash equivalent from operating activities as of March 2020 is around INR 323 Cr Vs. 98 Cr as of March 2019. The good thing is company is virtually debt free and giving good dividend which is around 8% of Current market price.
Position: Share strong support price is INR 3820/3680. Long term investor should continue with the company.
**Share View**: Share price high 5,172 (52 week) and now 4,078. PFizer in a wide range of research areas, including depression, erectile dysfunction, high cholesterol, HIV infection, hypertension, bacterial infections and systemic fungal infections. Pfizer has more than 150 products across 15 therapeutic areas.
Opportunities: Consistent dividend paying company and in this year paid dividend around 8% of CMP. MNC company with strong follow corporate governance model. Diversified business model for multiple health area focus. Strong operating cash flow with Zero debt.
Risk: Result is declined on YoY and QoQ , EBITDA also declined. Low return on equity around 14% for more than 3 years now. Single digit topline growth.
Disclaimer: Views are shared based on market research and study and personal in nature. Others can take the different view and opinions. Please do the thoroughly study before enter or exit the shares.
RD Stock (“High Returns with Low Risk is the Key”)
Like
Reply
NSE:PFIZER price when posted: 4,035.1
Recent posts in PFIZER

Type
Buy
Instrument
PFIZER
Entry Price
₹4,415
Price@Trade
₹4,415
Target Price
₹7,000
Stop Price
₹2,000
Valid Till
Aug 6, 2021 3:20 AM
Margin
₹22,075 approx for 5 Qty
Status
Active
Like
Reply
N
Reputation: 4,817 • Aug 3 3:31 AM
Pricing Covid-19 vaccines too high could backfire on big pharmaceutical companies
A world without global intellectual property would be one of constant electronic warfare. State-backed hacking, such as China apparently tried with Moderna this week, would be a constant threat. Nor would companies enjoy a comfortable relationship with their own governments, who would see them less as engines of growth and more as storehouses of national wealth.
The Economic Times
Like
Reply
N
Reputation: 4,817 • Jul 30 5:41 AM
'Vaccine nationalism': Is it one country against other in the race for a Covid-19 shot?
That's the fear of global health agencies planning a scheme to bulk-buy and equitably distribute vaccines around the world. They are watching with dismay as some wealthier countries have decided to go it alone, striking deals with drugmakers to secure millions of doses of promising candidates for their citizens.
The Economic Times
Like
Reply

*Pfizer Ltd.* | *CMP* Rs. 4371 | *M Cap* Rs. 19996 Cr | *52 W H/L* 4999/2612
(Nirmal Bang Retail Research)
*Result has improved*
Revenue from Operations came at Rs. 514.9 Cr (2.6% QoQ, -5.4% YoY) vs QoQ Rs. 502 Cr, YoY Rs. 544.4 Cr
EBIDTA came at Rs. 186.3 Cr (71.4% QoQ,...
Read more...
1
Reply

Type
Buy
Instrument
PFIZER
Entry Price
₹4,380.1
Price@Trade
₹4,380.1
Target Price
₹4,600
Stop Price
₹4,300
Valid Till
Aug 28, 2020 3:20 AM
Margin
₹87,602 approx for 20 Qty
Status
Stoploss Hit
Exit Price
₹4,300
Net P&L
-₹1,602 (-1.83%)
Like
Reply (2)
N
Reputation: 4,817 • Jul 28 3:28 AM
Pfizer Standalone June 2020 Net Sales at Rs 514.89 crore, down 5.42% Y-o-Y
Moneycontrol
Like
Reply